XRHealth expands into fibromyalgia with Swing Therapeutics acquisition

Fibromyalgia affects women in around 80–90% of cases

Therapeutics platform XRHealth has acquired digital therapeutics company Swing Therapeutics. The deal adds Stanza, the first digital behavioral therapy indicated for treatments of fibromyalgia, as well as Swing Care, the company’s specialist virtual clinic for fibromyalgia and chronic pain.

Fibromyalgia is a chronic pain condition with no cure affecting around 10 million people in the US and it is estimated to affect women in 80–90% of cases. The acquisition highlights how conditions that disproportionately affect women are increasingly becoming strategic priorities for larger healthcare companies.

Founded in 2019, Swing Therapeutics developed Stanza, now an FDA De Novo-authorised prescription digital therapeutic for fibromyalgia based on Acceptance and Commitment Therapy (ACT). In a Phase 3 randomised controlled trial published in The Lancet, the programme demonstrated significant improvements in fibromyalgia severity, pain intensity, fatigue, sleep and depression.

Beyond Stanza, Swing also built Swing Care, a virtual specialty clinic that combines the digital therapeutic with medication management, mental health support and personalised coaching. According to the company, 88% of patients reported an improvement in overall wellbeing after one year of treatment, with just over half saying they felt “much improved” or better.

For XRHealth, the acquisition expands its platform beyond virtual and augmented reality into smartphone-based digital therapeutics, wearable technologies and virtual care. The company, which is licensed across 22 US states and delivers care through Medicare, Veterans Affairs and commercial insurance, said the combined platform will bring together AI, licensed clinicians and multiple digital care technologies under a single reimbursable model.

“The future of therapeutic care is technology. Not as a supplement to medicine, but as the medicine itself - delivered through AI, monitored by licensed clinicians, reimbursed by insurance, and continuously improved by outcomes data,” said XRHealth CEO Eran Orr.

“We are building the infrastructure for the next era of medicine.”

Fibromyalgia has historically received relatively little attention despite affecting millions of people, the vast majority of whom are women. Rather than remaining the focus of specialist companies, it is increasingly becoming part of broader healthcare platforms - another sign that conditions disproportionately affecting women are being integrated into mainstream healthcare.

Other innovations in the space include the CE-marked Remedee Labs device, NeuroMetrix’s Quell device, and the newly FDA-approved medication Tonmya.

You may also like to read: